Stock Events

Stock Events

Search...

Regulus Therapeutics

€1.34

19

+€0+0% Wednesday 06:00

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

89.69M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

7NovExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-0.44

-0.34

-0.24

-0.15

Expected EPS

-0.17

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7RG0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Regulus's focus on microRNA.

Ionis Pharmaceuticals

Ionis Pharmaceuticals develops antisense therapeutics, a similar approach to Regulus's RNA-based treatments.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is involved in developing RNAi therapeutics, competing in the same space as Regulus.

Moderna is known for mRNA therapeutics and vaccines, competing in the broader RNA-based treatment market.

Biomarin Pharmaceutical

BioMarin Pharmaceutical develops gene therapies, which can be seen as a competing approach to Regulus's RNA-focused treatments.

Sangamo Therapeutics

Sangamo Therapeutics works on genomic medicines, including RNA-based therapies, making it a competitor.

Novartis AG, a large pharmaceutical company, has a diverse portfolio that includes RNA-based therapies, competing on multiple fronts.

Pfizer has investments in RNA therapies and a broad portfolio that competes with smaller biotech firms like Regulus.

Roche Holding AG engages in the development of RNA-based drugs among its vast pharmaceutical portfolio, presenting competition.

About

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Show more...

CEO

Mr. Joseph P. Hagan M.B.A.

Employees

31

Country

US

ISIN

US75915K3095

WKN

000A3DNZ4

Listings